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Introduction: The pemetrexed-gemcitabine combination is effec-
tive in patients with non-small cell lung cancer (NSCLC). Preclin-
ical data suggest that pemetrexed may synergistically interact with
gemcitabine by enhancing the expression of human equilibrative
nucleoside transporter 1 (hENT1) and deoxycytidine kinase (dCK),
increasing the uptake and intracellular activation of gemcitabine. A
pharmacogenetic approach was adopted to evaluate hENT1 and
dCK expressions in humans and to identify the potential best time
interval to administer gemcitabine after pemetrexed in patients with
advanced NSCLC.
Methods: The dCK and hENT1 expressions, examined by quanti-
tative real-time polymerase chain reaction, were analyzed during
each cycle before and at 1, 2, 4, 6, 24, and 48 hours after pemetrexed
administration. The relative differences from baseline to each
planned time, for peak values and for the relative difference at peak,
were measured.
Results: Nineteen patients were treated with pemetrexed single
agent (500 mg/m2 every 15 or 21 days). Quantitative real-time
polymerase chain reaction analysis revealed a statistically significant
(p  0.001) biphasic increase in both hENT1 and dCK genes at 1 to
2 and 24 to 48 hours after pemetrexed administration.
Conclusions: This is the first evidence of dCK and hENT1 induction
by pemetrexed in humans, suggesting that the pemetrexed3gemcit-
abine combination should be optimized by the administration of gem-
citabine 1 to 2 or 24 to 48 hours after pemetrexed. These results support
further studies to validate the role of dCK/hENT1 in vivo modulation
for the optimization of gemcitabine-pemetrexed combination in patients
with NSCLC.
Key Words: dCK, hENT1, Gene expression, Pemetrexed,
Gemcitabine.
(J Thorac Oncol. 2011;6: 768–773)
Chemotherapy with platinum-based doublets represents thebackbone of treatment for advanced non-small cell lung
cancer (NSCLC),1 but the lack of balance between therapeutic
activity and toxicity supports the research of novel platinum-free
combinations, together with the availability of third-generation
drugs. Among these, pemetrexed has shown to be active in
NSCLC, with a suggested major antitumor activity in nonsqua-
mous tumor types,2 and having a favorable toxicity profile,3
which makes this drug an attractive agent for combined regi-
mens with other active cytotoxics.
Pemetrexed is a novel agent that acts on several folate
metabolism enzymes, which are involved in DNA synthesis
and cell death control.4–6 In particular, deoxycytidine triphos-
phate depletion and glycinamide ribonucleotide formyltrans-
ferase inhibition induced by pemetrexed might enhance the
expression of the key genes involved in gemcitabine transport
and metabolism, as reported in several preclinical cancer
models, including NSCLC cells.7,8
Gemcitabine is a deoxycytidine analog, which activity
depends on the ribonucleotide reductase enzyme inhibition
and on drug incorporation into the DNA during the S phase.
Because of its hydrophilicity, gemcitabine does not cross the
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cellular membrane by diffusion, and it is transported into
cells by the human equilibrative nucleoside transporter 1
(hENT1). After cellular uptake, gemcitabine must be phos-
phorylated to its active metabolites by the enzyme deoxycy-
tidine kinase (dCK). These two passages are rate-limiting
steps for gemcitabine activation, and the higher expression of
dCK and hENT1 has been associated with gemcitabine sen-
sitivity in NSCLC cells. Several in vitro experiments showed
that the sequence pemetrexed3gemcitabine is more active
than gemcitabine3pemetrexed.7,9,10
The synergistic interaction of pemetrexed-gemcitabine
was associated with the induction of the dCK and hENT1
expressions by pemetrexed. These preclinical data are con-
sistent with the results of a phase I trial11 and a randomized,
phase II trial testing three different schedules of pemetrexed
and gemcitabine in combination.12 This evidence was also
supported by a recent phase II study in patients with NSCLC,
where the gemcitabine3pemetrexed combination was mini-
mally active, with a high incidence of grade 3 or 4 toxic
effects, requiring frequent dose adjustments.13 Nevertheless,
definitive evidence of the synergistic modulation of gene
expression in humans is missing, and no information is
currently available regarding the optimum time interval be-
tween these two drugs. Answering these questions by the
“clinical evidence-based methodology” should require a mul-
tiarm, randomized, controlled trial, which, if designed in the
absence of proper information, would present with inherent
disadvantages such as the high cost involved and the need for
a large sample size. To explore whether a synergistic inter-
action between pemetrexed and gemcitabine is reproducible
in humans and to determine the most effective interval
between the two drugs, a pharmacogenetic approach has been
adopted in this study. Therefore, both the dCK and hENT1
expressions have been examined as a surrogate end point,
using freshly isolated lymphocytes, at various time intervals,
up to 48 hours after pemetrexed administration, in patients
with advanced NSCLC.
PATIENTS AND METHODS
Patients with histological or cytological evidence of
stage IIIB and stage IV NSCLC and not suitable for platinum-
containing regimens or pretreated with regimens not contain-
ing gemcitabine or pemetrexed were eligible for this study.
Other eligibility criteria included age 18 years; Eastern
Cooperative Oncology Group performance status (PS) 2;
estimated life expectancy of at least 12 weeks; adequate bone
marrow (platelets 100  109 cells/L, absolute neutrophil
count 1.5  109 cells/L, and hemoglobin 9 g/dl); hepatic
(total bilirubin,1.5 times the upper limit of normal, alkaline
phosphatase, aspartate transaminase, and alanine transami-
nase 3.0  upper limit of normal. Aspartate transaminase
and alanine transaminase 5.0  upper limit of normal were
acceptable if documented liver metastases were present.); and
renal (calculated creatinine clearance, 45 ml/min, using the
standard Cockcroft calculated creatinine clearance formula)
functions.
Exclusion criteria included symptomatic or active brain
metastasis, diagnosis of significant cardiac disease, pregnant
or nursing women, radiation therapy to more than 25% of
bone marrow, inability to discontinue therapy with aspirin at
doses more than 1.3 g/d or nonsteroidal antiinflammatory
drug therapy for a 5-day period, clinically significant pleural
or peritoneal effusions, and diagnosis of myocardial infarc-
tion or significant cardiac disease. Patients were excluded
from the study also if they had received treatment within the
last 30 days with a drug (not including study drug) that had
not received regulatory approval for any indication at the time
of study entry. This pilot study complies with the ethical
standards laid down in the 1964 Declaration of Helsinki.
Ethics committee approval was taken, and written informed
consent was obtained from all patients enrolled in the study
(H3E-IT-S105).
Pemetrexed was supplied as lyophilized powder by Eli
Lilly & Company and reconstructed in sodium chloride
solution before use. Patients received pemetrexed at a dose of
500 mg/m2 as a 10-minute intravenous infusion at one of the
following schedules: once every 15 days (before amendment,
n  12) or once every 21 days (after amendment, n  7).
Dexamethasone (4 mg), or equivalent corticosteroid,
was given orally twice a day, starting the day before and
continuing until the day after study drug administration. Folic
acid (450 g) was administered orally daily beginning 1 to 2
weeks before first pemetrexed administration and for the
entire study duration. Vitamin B12 (1000 g) was given as
intramuscular injection every 9 weeks starting 4 weeks before
the first dose of pemetrexed and continuing until 3 weeks
after discontinuation of study therapy. Treatment was contin-
ued for a maximum of six of eight cycles (before/after
amendment) or until documented disease progression, unac-
ceptable toxicity, or patient refusal.
Isolation of Peripheral Blood Mononuclear Cells
During the first three cycles, 15 ml of blood was
withdrawn from a forearm peripheral vein at 1-, 2-, 4-, 6-,
24-, and 48-hour intervals after pemetrexed administration.
Whole blood was collected using BD-Vacutainer CPT, and
the separation of mononuclear cells was performed on a
Lymphoprep Separation Medium (Gibco Biology Research
Laboratories) following manufacturer’s instructions. Total
cellular RNA was then isolated from mononuclear cells using
Qiagen RNeasy Mini kit.
Quantitative Real-Time Polymerase Chain
Reaction
RNA (50–500 ng) was reverse transcribed with a Script
complementary DNA (cDNA) Synthesis kit (BioRad). cDNA
amplification was performed on a 7900HT sequence detec-
tion system (Applied Biosystems, Foster City, CA). Forward
and reverse primers and probes were designed with Primer
Express 2.0 based on dCK gene sequence obtained from
GenBank, whereas primers and probes for hENT1 were
obtained from Applied Biosystems Assay-on-Demand prod-
ucts. Validation experiments were carried out with cDNA
obtained from quantitative polymerase chain reaction human
reference total RNA to show that the efficiencies of amplifi-
cation of the target and the reference genes glyceraldehyde
3-phosphate dehydrogenase were approximately equal. Reac-
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tions were performed in triplicates, and polymerase chain
reaction (PCR) reagents and primers, without RNA as reac-
tion-negative controls, were added to each real-time PCR
assay. The coefficient of variation was less than 2% for all
replicates.
To support the study rationale, quantitative real-time
PCR analysis was also performed in healthy subjects (n  6,
four men and two women; mean age: 34 years, 30–44 years)
in absence of diabetes, cardiovascular, inflammatory or au-
toimmune disease, cancers, obesity, or any other chronic
disease in their clinical history. This evaluation was sponta-
neously performed by investigator site, earlier than study
initiation, to assess baseline values (and potential picks) of
dCK and hENT1, at sequential time intervals, without pem-
etrexed and related premedication exposure. An informed
consent was provided by all the volunteers.
Statistical Methods
Summary statistics were calculated for original values
of dCK and hENT1, for the relative differences from baseline
to each planned time, for the peak values, and for the relative
difference at peak, by cycle. The 95% confidence interval for
the mean peak value and for the relative difference at mean
peak was calculated. A multivariate repeated-measures anal-
ysis of variance on dCK and hENT1 values was performed to
test the main effect of cycle, the main effect of time, and the
interaction effect of cycle-x-time. Descriptive statistics were
provided for objective tumor response.
RESULTS
Patient Characteristics
From September 2006 to March 2008, 19 patients with
histologically or cytologically proven IIIB and IV NSCLC
were enrolled (Table 1).
All patients completed at least one cycle of treatment
and were included in the intention-to-treat (ITT) population.
After the enrolment of the first 12 patients, the pemetrexed
schedule was changed, from a 2-week to a 3-week regimen,
adopted in further seven patients.
Because of the higher rate of toxicities requiring recur-
rent delays in pemetrexed biweekly administration, the pro-
tocol was amended, to change the biweekly schedule and
restore the standard one (q21 schedule). What needs to be
highlighted is that as this is a pilot study, with the aim of
assessing both dCK and hENT1 expressions after pemetrexed
administration only, patient selection was not so strict, and
also patients with comorbidities and poor PS were enrolled.
Out of 19 enrolled patients, two (10.5%), two (10.5%),
one (5.3%), four (21.1%), two (10.5%), two (10.5%), three
(15.8%), three (15.8%) patients received one, two, three,
four, five, six, seven, and eight cycles, respectively.
One patient with baseline total bilirubin above the
required limit was enrolled with sponsor approval and was
excluded from the per-protocol population (n  18).
Six (31.6% of total) subjects completed the study,
whereas 13 (68.4%) were prematurely discontinued. Adverse
events (AEs) (seven patients, 36.8%) and disease progression
(four patients, 21.1%) were the causes of early withdrawal.
Two patients (10.5%) discontinued the study due to Investi-
gator’s decision for lack of drug efficacy.
Expression of dCK and hENT1 in Patients After
Pemetrexed Administration
In the entire study, the results of dCK and hENT1 peak
values (mean  SD) were 0.99  0.03 and 0.93  0.03,
respectively, whereas the relative differences at dCK and
hENT1 peak were 7.82 2.15 and 8.54 3.12, respectively.
Mean dCK percent differences at peak (SD) were 6.65 
2.33 at cycle1, 6.68 2.25 at cycle 2, and 6.93 1.26 at cycle
3, whereas for hENT1, the percent difference at peaks was
higher at cycle 2 (7.31  3.12) than at the other two cycles,
cycle 1 (5.63  2.45) and cycle 3 (6.56  1.66). The results of
dCK and hENT1 expressions reported as mean values evaluated
at the various interval times at cycle 1, cycle 2, and cycle 3 in the
overall ITT population are listed in Table 2.
The repeated measures analysis of variance showed a
statistically significant time effect (p  0.001) in both genes
expression. A statistically significant (p  0.0001) increase
from baseline was observed in mean values of the hENT1 and
dCK expressions after 1, 2, 24, and 48 hours (irrespective of
the cycle). The dCK mean values were smaller but signifi-
cantly different also at 4 hours (p  0.030), but the hENT1
mean values were not (p  0.333). At 6 hours, expression
levels were lower than baseline for both hENT1 and dCK
TABLE 1. Demographic and Disease Characteristics
Continuous Variables Mean  SD
Age (yr) 69.2  8.9
Weight (kg) 68.7  13.1
Height (cm) 166.4  10.1




History of previous antitumor treatment
Patients pretreated 13 (68.4)






Squamous cell carcinoma 6 (31.6)
Other 2 (10.5)
Histological grading
G1: well differentiated 2 (10.5)
G2: moderately differentiated 3 (15.8)
G3: poorly differentiated 5 (26.3)





SD, standard deviation; ECOG, Eastern Clinical Oncology Group; G, grading.
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values, but these differences were not statistically significant
(p  0.849 and p  0.166, respectively). The cycle effect
resulted statistically significant only in hENT1 expression
(p  0.037). The comparison of cycle 2 and cycle 3 versus
cycle 1 showed statistically significant differences (p 0.014
between cycle 2 and cycle 1, and p  0.016 between cycle 3
and cycle 1) in hENT1 expression and not in dCK expression.
The mean changes, expressed as percentage, from base-
line of dCK and hENT1 expressions revealed a significantly
marked increase after 1, 2, 24, and 48 hours at any cycle, a
smaller increase after 4 hours, and a nonsignificant decrease
after 6 hours (Figures 1 and 2).
No substantial differences between the two schedules
of administration were observed in the dCK and hENT1
expressions measured in any cycle. Results from the per-
protocol population were consistent with those observed in
the ITT population.
The quantitative real-time PCR analysis performed in
the healthy subjects revealed that both the dCK and hENT1
gene expression were unchanged over the predefined time
intervals (throughout 48 hours). Baseline dCK (0.93  0.02)
and hENT1 (0.83  0.02) values in the patient population
were similar to baseline levels in healthy subjects.
Evaluation of Tumor Response (RECIST
Criteria)
At the end of the study, one patient (5.3%) had partial
response, six (31.6%) had confirmed stable disease, eight
(42.1%) did not have confirmed stable disease (not confirmed
within 6 weeks after the first observation), three (15.8%) had
progression of disease, and one patient died prematurely.
Overall, seven were responders and 12 were not. The re-
sponse rate was 57.1% in patients treated with a 3-week
regimen and 25.0% in those treated with the 2-week regimen.
Safety
All AEs assessment was performed during study
treatment.
AEs were reported on a per-subject basis. This means
when a patient experiences the same AE repeatedly, the event
is counted once only.
Five patients (26.3%) experienced serious AEs (SAEs).
Out of five patients (26.3%) who experienced SAEs, only one
patient reported drug-related SAEs (bleeding and thrombo-
cytopenia). All other SAEs should be considered as a conse-
quence of tumor progression.
Drug-related AEs were reported in 18 patients (94.7%),
whereas in 16 patients (84.2%), the dose was modified or the
treatment prematurely interrupted due to AEs. Grade 3 and
grade 4 AEs are listed in Table 3.
FIGURE 1. Mean changes (%) from baseline of deoxycyt-
idine kinase (dCK) expression evaluated at cycle 1, cycle 2,
and cycle 3 in the overall intention-to-treat (ITT) population.
FIGURE 2. Mean changes (%) from baseline of human
equilibrative nucleoside transporter-1 (hENT1) expression
evaluated at cycle 1, cycle 2, and cycle 3 in the overall in-
tention-to-treat (ITT) population.
TABLE 2. Mean  SD dCK and hENT1 Expressions Evaluated at Cycle 1, Cycle 2, and Cycle 3 in the Overall ITT Population
dCK hENT1
Cycle 1 Cycle 2 Cycle 3 Cycle 1 Cycle 2 Cycle 3
Baseline 0.92  0.03 0.92  0.03 0.92  0.02 0.86  0.03 0.86  0.03 0.87  0.02
1 h 0.96  0.04 0.95  0.03 0.96  0.03 0.88  0.04 0.89  0.04 0.90  0.03
2 h 0.96  0.04 0.96  0.04 0.97  0.02 0.88  0.04 0.90  0.04 0.90  0.04
4 h 0.93  0.04 0.94  0.04 0.92  0.03 0.86  0.04 0.88  0.05 0.86  0.03
6 h 0.92  0.03 0.91  0.04 0.91  0.03 0.86  0.04 0.86  0.04 0.86  0.02
24 h 0.96  0.04 0.97  0.03 0.96  0.03 0.89  0.04 0.91  0.04 0.91  0.02
48 h 0.97  0.04 0.96  0.04 0.97  0.03 0.90  0.04 0.91  0.04 0.91  0.02
ITT, intention to treat; SD, standard deviation; hENT1, human equilibrative nucleoside transporter 1; dCK, deoxycytidine kinase.
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As the primary objective of this pilot study is to assess
and evaluate both dCK and hENT1 expressions after pem-
etrexed administration, patient selection was not so tight, and
poor PS patients or with comorbidities were also enrolled.
That is probably the reason why a higher toxicity rate was
observed.
Therefore, as recent evidences documented that pa-
tients with locally advanced or metastatic NSCLC could
benefit from pemetrexed given on a 3-week schedule, with a
low incidence of hematological and nonhematological toxic-
ities,14,15 a protocol amendment was issued to change the
initial dose regimen (q15) to a 3-week schedule (q21), which
applied to the last seven patients.
DISCUSSION
The pemetrexed-gemcitabine combination seemed to
be effective in NSCLC.
The schedule pemetrexed followed by gemcitabine
seems to be more active than the sequence gemcitabine3
pemetrexed. This evidence is supported by in vitro experi-
ments7,9,10 and by a randomized, phase II study, in patients
with NSCLC.12 The schedule with pemetrexed followed by
gemcitabine on day 1 and gemcitabine on day 8, with a
confirmed response rate of 31%, met the protocol-defined
efficacy criteria, whereas the schedule with gemcitabine on
day 1 and pemetrexed followed by gemcitabine on day 8,
with a confirmed response rate of 16%, did not.12 Similarly,
a recent trial13 evaluating the activity of gemcitabine fol-
lowed by pemetrexed in patients with advanced NSCLC
found an overall response rate of 13%, with a similarly
disappointing progression-free survival.
Nevertheless, a recent phase II trial to assess the ob-
jective response rate and safety of first-line biweekly gem-
citabine and pemetrexed in patients with NSCLC older than
70 years was closed after only nine patients due to unaccept-
able toxicity.16 Although other studies showed that the pem-
etrexed-gemcitabine schedule is well tolerated in elderly
patients,17–20 particularly frail patients can experience an
excess of toxicities with a 2-week regimen, as we observed in
our trial, where the protocol was amended to change the
biweekly schedule and restore the standard one (3-week
regimen).
Therefore, pemetrexed and gemcitabine administration
should be further investigated. Moreover, definitive evi-
dences of the possible mechanisms underlying their synergis-
tic antitumoral activity in humans are still missing, and no
information is available regarding the optimum time interval
between the administrations of these two drugs.
In this study, a pharmacogenetic approach was adopted to
explore whether the synergistic interaction on gene expression
modulation between pemetrexed and gemcitabine is reproduc-
ible in humans and to determine the most meaningful interval to
administer the two drugs. The expression of the main transporter
and the key enzyme in the rate-limiting step of gemcitabine
activation were measured in lymphocytes, at various intervals up
to 48 hours, after pemetrexed administration, to explore whether
the administration of this drug could induce an increase in their
levels, suggesting a synergism between pemetrexed followed by
gemcitabine, and to evaluate whether there was a reproducible
timing of maximum dCK and hENT1 expressions to be used as
the most appropriate interval between the administration of the
two drugs.
The study confirmed the modulation of the dCK and
hENT1 expressions induced by pemetrexed, showing a statisti-
cally significant increase of both variables at 1, 2, 24, and 48
hours from pemetrexed administration, irrespective of the cycle
and of the 3- or 2-week schedule. Baseline values of both
hENT1 and dCK were increased at 1 hour, in all patients.
Before study initiation, the specific gene expression
was also quantified in six healthy subjects, showing baseline
dCK and hENT1 levels, not being altered over the predefined
time intervals (throughout 48 hours). These evidences sup-
ported the idea that the changes in gene expression observed
in patients with NSCLC were specifically related to pem-
etrexed administration.
Moreover, univariate explorative regression analysis,
which examined the potential relationship of dCK and
hENT1 baseline values, and both peak values, with many
different variables (e.g., demographic characteristics, dose of
study drugs, tumor response, vital signs, and laboratory
parameters) did not show significant correlation, demonstrat-
ing that changes in gene expression were not determined by
patient clinical characteristics.
The activation peak, occurring at 1 to 2 hours after
pemetrexed infusion, is aligned with the results of the previ-
ous randomized, phase II trial where pemetrexed on day 1,
followed 90 minutes later by gemcitabine on days 1 and 8,
was less toxic and met the protocol-defined efficacy criteria.12
Furthermore, the 24-hour peak after pemetrexed administra-
tion supports an activation pattern similar to the modulation
of dCK and hENT1 gene expression underlying the synergis-
tic cytotoxicity of the pemetrexed3gemcitabine combination
in NSCLC cells.7
Although the extrapolation of in vitro data to the in vivo
setting should be considered with caution, these studies
suggested that even small changes in gene expression/activity
could make a difference in drug efficacy, and our pilot
clinical trial should prompt further clinical studies to evaluate





G 3 G 4 G 3 G 4
Hematologic, n (%) 5 (41.7) 1 (8.3) 0 (0) 1 (14.3)
Neutropenia 2 (16.7) 0 (0) 0 (0) 1 (14.3)
Thrombocytopenia 1 (8.3) 0 (0) 0 (0) 0 (0)
Leukopenia 2 (16.7) 1 (8.3) 0 (0) 0 (0)
Nonhematologic, n (%)
Constipation 1 (8.3) 0 (0) 0 (0) 0 (0)
Diarrhea 1 (8.3) 0 (0) 0 (0) 0 (0)
Asthenia 1 (8.3) 0 (0) 1 (14.3) 0 (0)
Transaminase alteration 1 (8.3) 0 (0) 2 (28.6) 0 (0)
G, grade; AE, adverse event.
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whether these changes can, at least in part, explain the
difference between the success and the failure of various
chemotherapy schedules.
Therefore, these results suggested a time-related ge-
netic synergism and do not support the suggestion to omit the
delay between the infusion of pemetrexed and gemcitabine,
which was just based on the absence of pharmacokinetic
interaction between gemcitabine and pemetrexed when ad-
ministered in rapid sequence.21,22 Nevertheless, the present
research is limited by its exploratory nature and the investi-
gation of the changes in gemcitabine uptake, and intracellular
activation would require further experiments and the study of
how these changes might improve drug efficacy would need
further clinical trials.
Preclinical and clinical studies show how dexametha-
sone might result in altered gene expression23,24 and reduce
sensitivity of lung cancer cells to gemcitabine.25 In the
current experience, the modulation of the dCK and hENT1
expressions, induced by pemetrexed, was highly reproducible
among all 19 patients, although receiving dexamethasone
premedication, as mandatory in clinical practice.
In conclusion, this is the first evidence of dCK and
hENT1 induction by pemetrexed in humans, suggesting that
the activity of the sequence pemetrexed3gemcitabine should
be optimized by the administration of gemcitabine 1 to 2 or
24 to 48 hours after pemetrexed. These results support further
studies to validate the role of dCK/hENT1 in vivo modulation
for the optimization of gemcitabine-pemetrexed combination
in patients with NSCLC.
Although limited by its exploratory nature, this study is
an example of how a pharmacogenetic approach may offer
the possibility of optimizing drug combinations, providing
with appropriate information to further explore the most
promising regimens in future randomized controlled trials.
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